Catheter Patent Extension Could Affect Medtronic DES

Medtronic's Endeavor drug-eluting stent has lagged behind Abbott's Xience V and other rivals because it is not sold with the rapid exchange catheter, a delivery system that a lot of cardiologists prefer. The patent is held by Abbott and expires this year. But Abbott is seeking a three-year extension on it until 2011, under a rule that sometimes allows patent holders to make up time that was lost waiting for regulatory approval.

October 7, 2008

1 Min Read
Catheter Patent Extension Could Affect Medtronic DES

So Medtronic has gone to court to try to get the extension request denied, Bloomberg News reports. If it succeeds, it will be able to sell the rapid exchange catheter when its patent expires on Oct. 29. A federal court heard arguments last week.Medtronic has been banned from selling the rapid exchange catheter with its products since 2001, when it lost a patent case where it was accused of selling a knockoff. The firm developed an alternative delivery system, but it never came in to favor with cardiologists. Before the rapid exchange catheter, stent delivery was a complicated process that took at least two people to perform.Endeavor holds about 12-15% of the DES market, compared to 50% for Xience and Boston Scientific's Promus, which is the same thing as Xience. Medtronic hopes that if Endeavor is sold with the rapid exchange catheter, it can close that gap.UPDATE: The U.S. Patent and Trademark Office granted a one-year patent extension to Abbott.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like